{"transactions":[{"id":1637377,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":349998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2024-03-15","expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":349998},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637376,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637375,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":true,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":1555,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637374,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"shares","element":"transactionShares","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637373,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":4171246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637372,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":1125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination."}],"balance_after":4171246,"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":2544072,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2021-10-12T23:41:26.000Z","date":"2021-10-08","kind":"other","acquired":true,"shares":18366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition by reporting person in connection with the partial exercise of the underwriters' over-allotment option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation."}],"balance_after":349998,"derivative":{"exercise_price":11.5,"underlying":"Class A Common Stock","underlying_shares":18366},"source":{"system":"sec-edgar","filing":"0000899243-21-039943","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000089924321039943/doc4.xml","form_type":"4"}},{"id":2544071,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2021-10-12T23:41:26.000Z","date":"2021-10-08","kind":"other","acquired":false,"shares":82875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date."}],"balance_after":4596250,"derivative":{"underlying":"Class A Common Stock","underlying_shares":82875},"source":{"system":"sec-edgar","filing":"0000899243-21-039943","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000089924321039943/doc4.xml","form_type":"4"}},{"id":2544070,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A common stock","published_at":"2021-10-12T23:41:26.000Z","date":"2021-10-08","kind":"other","acquired":true,"shares":36733,"price":10,"value":367330.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition by reporting person in connection with the partial exercise of the underwriters' over-allotment option."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares underlie the same number of units of the issuer held by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares underlie the same number of units of the issuer held by the reporting person."}],"balance_after":699996,"source":{"system":"sec-edgar","filing":"0000899243-21-039943","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000089924321039943/doc4.xml","form_type":"4"}}]}